When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

While the Dutch company expects to report profits up between 4% and 8% when it releases its full-year 2024 financial results ...

Investors are appraising Trump policies' likely impact on stocks on the last trading day before the inauguration.

The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...

Texas Instruments falls after the chip maker’s first-quarter earnings forecast misses estimates, Boeing declines after ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

The forecast places the stock at $59.84, representing a 32.07% increase from its current price of $45.31. Numerous factors have contributed to the stock's growth since 2024: By 2026, IonQ’s ...

Let’s breakdown how these predictions are made. Predicting stock prices involves more than just looking at a company’s financials and hoping for the best. Here’s the playbook: Many analysts ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

TD Cowen analyst Marc Bianchi has maintained their bullish stance on SLB stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...